Abstract: The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.

Abstract: The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.

Abstract: A blade for a turbomachine fan, the blade being made from a composite material containing a plurality of longitudinal conductive fibres embedded in an electrically non-conductive matrix, the blade having at least one fastening region to which an identification medium for identifying the blade is fastened, the fastening region containing longitudinal fibres oriented along a preferred fibre axis, the identification medium contains an item of identification data for identifying the blade and at least one radio antenna having at least one communication lobe configured so as to receive a read request and transmit the item of identification data in return, the communication lobe being oriented along a radio axis that is angularly offset from the preferred fibre axis by less than 45°, preferably by less than 22.5°.

Abstract: A method for extracting nucleic acids using suitable solid supports, for example silica-based. In particular, the method includes a step of capturing nucleic acids by placing the sample in contact with a suitable solid support, characterized in that, prior to the capture step, said method includes a step of treating the sample with at least one reagent for masking the amine or carboxylic acid functional groups of the proteins and/or polysaccharides of the sample.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

Abstract: A three-layer complex including at least one magnetic compound, at least one inorganic silicate and at least one compound having an affinity for the at least one magnetic compound and/or the at least one inorganic silicate. The three-layer complex, and associated methods, may be applicable in the field of in vitro diagnostics.

Abstract: Compounds having the Formula (I), and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (Formula I)) are useful as kinase inhibitors or modulators, including BTK modulation or inhibition, wherein X1, X2, m, m?, E and R1 are as defined herein.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly RLK (TXK). The present invention is directed to a compound of Formula (I) or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

Abstract: There is provided a method and system for authenticating a production of products. The method and system comprise determining if configuration data for the production run is authorized and, if the production run is authorized, generating a security token and associating the token with configuration data. The configuration data is digitally signed by generating a digital signature and associating the digital signature with the configuration data. The digital signature associated with the digitally signed configuration data is verified. Products are then produced in a production run according to the digitally signed configuration data, and the set of secure product identifiers is printed on the products according to the digitally signed configuration data.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.

Abstract: The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

Abstract: A method of functionalizing RNA in a liquid sample includes reacting an anhydride function of a binding molecule with at least one RNA molecule at one or more hydroxyl groups in any of position 2? of a ribose of any nucleotide of the RNA molecule, position 2? of the ribose of the terminal nucleotide at the 3? end of the RNA molecule, or position 3? of the ribose of the terminal nucleotide at the 3? end of the RNA molecule, to obtain functionalized RNA. The binding molecule includes an aza-isatoic anhydride or derivative thereof linked to a group of interest by a linkage, and an aza-anthranilate is formed from reacting the anhydride function of the binding molecule with a hydroxyl group of the RNA molecule so as to join the RNA molecule to the group of interest. The group of interest is a marker, labelling precursor, or ligand.

Abstract: The present invention relates to a method of functionalization of at least one ribonucleic acid (RNA) molecule, contained in a liquid sample, which includes the following steps: a) providing at least: one binding molecule consisting of an aza-isatoic anhydride or a derivative thereof, one group of interest, and one linkage joining the binding molecule to the group of interest, b) reacting the anhydride function of the binding molecule with at least one hydroxyl group carried: in position 2? of the ribose of one of the RNA nucleotides, and/or in position(s) 2? and/or 3? of the ribose of the nucleotide at the terminal 3? end of the RNA, and obtaining an aza-anthranilate that joins, by means of the linkage, the RNA to the group of interest.

Abstract: The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.

Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

Abstract: There is provided a method and system for authenticating a production of products. The method and system comprise determining if configuration data for the production run is authorized and, if the production run is authorized, generating a security token and associating the token with configuration data. The configuration data is digitally signed by generating a digital signature and associating the digital signature with the configuration data. The digital signature associated with the digitally signed configuration data is verified. Products are then produced in a production run according to the digitally signed configuration data, and the set of secure product identifiers is printed on the products according to the digitally signed configuration data.